As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

In a report released today, Mohit Bansal from Wells Fargo maintained a Hold rating on Biogen (BIIB – Research Report), with a price ...

Bernstein started coverage of Eli Lilly (NYSE:LLY), Gilead Sciences (NASDAQ:GILD) and Amgen (NASDAQ:AMGN) with outperform ...

Jefferies analyst Michael Yee maintained a Buy rating on Biogen (BIIB – Research Report) today and set a price target of $250.00. The ...

The prevailing sentiment among analysts is an Neutral trajectory for Amgen, with an average 1-year price target of $347.8, implying a potential 287.13% upside. Gilead Sciences ranks in the middle ...

"The global regenerative medicine markets comprises of many key market players competing for markets shares like Novartis AG ...

Truist Securities analyst Asthika Goonewardene in an investor note said data for anito-cel—particularly its safety ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In the latest quarter, 15 analysts provided ratings for Gilead Sciences (NASDAQ:GILD), showcasing a mix of bullish and bearish perspectives. The following table summarizes their recent ratings ...

Gilead Sciences (NASDAQ:GILD) will release its quarterly earnings report on Wednesday, 2024-11-06. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Gilead ...